With recommendations to stay at home this winter to help stop the spread of COVID-19, David Mischoulon, MD, PhD, offers insights on SAD and how to stay well at home this winter.
BOSTON—Many patients with severe coronavirus disease 2019 (COVID-19) remain unresponsive after surviving critical illness. Investigators led by a team at Massachusetts General Hospital now describe a patient with severe COVID-19 who, despite prolonged unresponsiveness and structural brain abnormalities, demonstrated functionally intact brain connections and weeks later he recovered the ability to follow commands. The case, which is published in the Annals of Neurology, suggests that unresponsive patients with COVID-19 may have a better chance of recovery than expected.
In addition to performing standard brain imaging tests, the team took images of the patient’s brain with a technique called resting-state functional magnetic resonance imaging (rs-fMRI), which evaluates the connectivity of brain networks by measuring spontaneous oscillations of brain activity. The patient was a 47-year-old man who developed progressive respiratory failure, and despite intensive treatment, he fluctuated between coma and a minimally conscious state for several weeks.
Brian Edlow, MD
Our unexpected observations do not prove that functional MRI predicts outcomes in these patients, but they suggest that clinicians should consider the possibility that unresponsive survivors of severe COVID-19 may have intact brain networks.
Senior author of the study and Mass General physician
Standard brain imaging tests revealed considerable damage, but unexpectedly, rs-fMRI revealed robust functional connectivity within the default mode network (DMN), which is a brain network thought to be involved in human consciousness. Studies have shown that stronger DMN connectivity in patients with disorders of consciousness predicts better neurologic recovery. The patient’s DMN connectively was comparable to that seen in healthy individuals, suggesting that the neurologic prognosis may not be as grim as conventional tests implied.
Twenty days later, on hospital day 61, the patient began following verbal commands. He blinked his eyes to command, opened his mouth to command and on day 66 followed four out of four vocalization commands. By this time, he also consistently demonstrated gaze tracking with his eyes in response to visual and auditory stimuli.
“Because there are so many unanswered questions about the potential for recovery in unresponsive patients who have survived severe COVID-19, any available data that could inform prognosis are critical,” said senior author Brian Edlow, MD, director of the Laboratory for NeuroImaging of Coma and Consciousness and associate director of the Center for Neurotechnology and Neurorecovery at Mass General. “Our unexpected observations do not prove that functional MRI predicts outcomes in these patients, but they suggest that clinicians should consider the possibility that unresponsive survivors of severe COVID-19 may have intact brain networks. We should thus exercise caution before presuming a poor neurologic outcome based on our conventional tests.”
Providing families with an accurate prognosis about neurological recovery is particularly challenging for patients with COVID-19, because so little is known about how the brain is affected by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), or associated inflammation and clotting disorders. “Initially, our goal in the intensive care unit was to support patients through the critical illness of COVID-19,” said lead author David Fischer, MD, neurocritical care fellow at Mass General. “However, we found that a subset of patients, after surviving the critical illness, were not waking up as expected. As neurologists, we were asked by many families whether their loved ones would regain consciousness—a critical question given that decisions about life support often hinged on the answer—but we were uncertain. We used functional MRI to try to provide a more comprehensive assessment of brain function.”
The application of functional MRI to critically ill patients with disorders of consciousness is the culmination of decades of work to develop this technology and ultimately translate it to clinical care. Co-author Bruce Rosen, MD, PhD, director of the Athinoula A. Martinos Center for Biomedical Imaging at Mass General, and one of the developers of functional MRI in the early 1990s, explained that “we have to be cautious when interpreting results from a single patient, but this study provides proof of principle that clinicians may be able to use advanced imaging techniques like functional MRI to get a clearer picture of a patient’s brain function, and hence the potential for recovery.”
To facilitate dissemination of this tool to other hospitals around the world caring for patients with COVID-19, the investigators release the functional MRI sequence parameters and the data analysis pipeline at www.github.com/ComaRecoveryLab/COVID-19_rsfMRI.
This work was supported by the James S. McDonnell Foundation COVID-19 Recovery of Consciousness Consortium.
About Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $1 billion and comprises more than 8,500 researchers working across more than 30 institutes, centers and departments. In August 2019 Mass General was once again named #2 in the nation by U.S. News & World Report in its list of "America’s Best Hospitals."
- Jan | 20 | 2021
Episode #51 of the Charged podcast
- Jan | 20 | 2021
View frequently asked questions and guidance about the COVID-19 vaccine for Cancer Center patients.
- Patient Education
- Jan | 19 | 2021
Get data and expert opinions about receiving the COVID-19 vaccine while pregnant or breastfeeding.
- Jan | 19 | 2021
Mai Uchida, MD, shares her “My Why”—outlining her decision to get the COVID vaccine during her pregnancy. Dr. Uchida hopes that she can be of help to anyone struggling with a similar decision by sharing her thought process, her emotions as a mother and her expertise as a physician.
- Patient Education
- Jan | 18 | 2021
2020年12月，美国食品药品监督管理局（FDA）批准了两款新型冠状病毒疫苗（辉瑞（Pfizer）/拜恩泰科（BioNTech）和莫德纳（Moderna））的紧急使用授权，这两款疫苗已经在全美范围内开始分发。麻省总医院的疫苗和免疫疗法中心主任Mark Poznansky, MD, PhD对有关对抗新型冠状病毒最新进展的常见问题给出了指导和答案。